MCM
ASMB icon

Monimus Capital Management’s Assembly Biosciences ASMB Stock Holding History

Monimus Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
47,580
-810
-2% -$22.1K 0.3% 52
2026
Q1 		$1.34M Buy
48,390
+10,089
+26% +$288K 0.37% 50
2025
Q4 		$1.3M Sell
38,301
-3,766
-9% -$121K 0.86% 39
2025
Q3 		$1.08M Hold
42,067
– – 0.66% 42
2025
Q2 		$762K Hold
42,067
– – 0.55% 46
2025
Q1 		$402K Hold
42,067
– – 0.34% 42
2024
Q4 		$664K Buy
+42,067
New +$677K 0.63% 41

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Monimus Capital Management's ASMB Position: Q2 2026 in Review

Monimus Capital Management reduced its Assembly Biosciences (ASMB) stake by 1.7% in Q2 2026, selling an estimated $22.1K and leaving 47,580 shares worth $1.31M. The position accounts for 0.3% of the portfolio, ranked #52.

Monimus Capital Management first reported a position in ASMB in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.34M in Q1 2026. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Monimus Capital Management held 47,580 shares of Assembly Biosciences worth $1.31M as of Q2 2026.
  • Monimus Capital Management sold 810 Assembly Biosciences shares in Q2 2026, an estimated $22.1K.
  • Assembly Biosciences made up 0.3% of Monimus Capital Management's portfolio in Q2 2026, its #52 holding.
  • Monimus Capital Management first reported a position in Assembly Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Monimus Capital Management's Assembly Biosciences position peaked at $1.34M in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Monimus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.